

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-3800015, Gujarat.

Phone: +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

February 10, 2024

To The Manager, Listing Department National Stock Exchange of India Ltd. Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department BSE Limited Phiroze Jeejabhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960
---	---

Dear Sir/Ma'am,

Sub.: Press Release- For the Third quarter and Nine month ended December 31, 2023

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith extracts of the Standalone and Consolidated Unaudited Financial Results for the Third quarter and Nine months ended December 31, 2023 as published in the below Newspapers on February 10, 2024.

The Details of the publications are as follows:

Sr.No.	Newspaper	Language	Editions
1	Financial Express	English	All
2	Financial Express	Gujarati	Ahmedabad

Further, in terms of Regulation 46 of the Listing Regulations, the aforesaid financial results are also uploaded on the website of the Company (www.concordbiotech.com)

Kindly take the above on records.

Thanking you,

For Concord Biotech Limited

Prakash Sajnani
Company Secretary and Compliance Officer
M. No. F6242

Encl: as above



Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

Registered Office: No. 1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India. Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(Amount in INR crores except per share data)

Table with 13 columns: Particulars, Quarter ended (31-Dec-23, 30-Sep-23, 31-Dec-22), Nine Months ended (31-Dec-23, 31-Dec-22), Year ended (31-Mar-23), and Standalone Quarter ended (31-Dec-23, 30-Sep-23, 31-Dec-22), Nine Months ended (31-Dec-23, 31-Dec-22), Year ended (31-Mar-23).

The unaudited consolidated and standalone financial results of the Company for the quarter and nine months ended December 31, 2023 have been reviewed by the Audit Committee on February 08, 2024 and approved by the Board of Directors at its meeting held on February 08, 2024.

For Aster DM Healthcare Limited Sd/- Alisha Moopen Deputy Managing Director DIN: 02432525

Place: Dubai Date: February 08, 2024

CONCORD BIOTECH LIMITED

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat Phone No. : +91-79-68138700 || Fax : +91-79-68138725 || CIN : L24230GJ1984PLC007440 Email Id : complianceofficer@concordbiotech.com || Website : www.concordbiotech.com Regd. Office & Plant : 1482-86, Trasad Road, Dhoika, District : Ahmedabad - 382225, Gujarat, India Phone No. : +91-2714-222604, 398200 || Fax : +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

(Rs. In lakhs except per share data)

Table with 7 columns: Particulars, Standalone (Unaudited) Quarter ended, Nine Months ended, Consolidated (Unaudited) Quarter ended, Nine Months ended, and Year ended.

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly / Nine Months Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Place : Ahmedabad Date : February 8, 2024 Joint Managing Director & CEO - DIN : 01857225

Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]



Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, KhoraJ (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481 Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com CIN : L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023

Rupees in Million

Table with 7 columns: Sr. No., Particulars, 3 Months ended, Preceding 3 Months ended, Corresponding 3 Months ended, Year to date figures for the current period ended, and Previous year ended.

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

By Order of the Board, For Zydus Lifesciences Limited, Dr. Sharvil P. Patel Managing Director DIN: 00131995

Date: February 9, 2024 Place: Ahmedabad



PSP Projects Limited

CIN :L45201GJ2008PLC054868 Registered Office : PSP House, Opp. Celesta Courtyard, Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058 Website : www.pspprojects.com

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023

(₹ in Lakhs)


Table with 4 columns: Sr. No., Particular, Quarter Ended, and Nine Months Ended.

Notes: 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 09, 2024.

Additional information on Unaudited Standalone Financial Results are as follows: (₹ in Lakhs)

Table with 4 columns: Particular, Quarter Ended, and Nine Months Ended.

3. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.



CIN:U65929MH1990PLC057829 Regd. Office: AVINISHA TOWER,MEHADIA CHOWK, DHANTOLI, NAGPUR - 440 012. Ph no.0712-6663999 Website: www.berarfinance.com E-mail: investor.relations@berarfinance.com

Extract of Financial Results for the quarter ended December 31, 2023

[Regulation 52(8) read with Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)]

(₹ in Lakhs, except per equity share data and Debt Equity Ratio)

Table with 4 columns: Sr. No., PARTICULARS, Quarter ended, and Year ended.

Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind AS Rules. * Not annualised for quarter ended December 31, 2023 and December 31, 2022.

Notes : a) The above Results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on February 09, 2024.

For and on behalf of Board of Directors of Berar Finance Limited Sd/- (Sandeep Jawanjal) Managing Director DIN: 01490654

Place: Nagpur Date: February 09, 2024



National Commodity & Derivatives Exchange Limited

CIN : U51909MH2003PLC140116

Regd Office : Akruji Corporate Park, 1st Floor, L.B.S. Road, Near G.E.Garden, Kanjurmarg West, Mumbai, Maharashtra 400078

Ph: 022-66406789 | Email: askus@ncdex.com | Website: www.ncdex.com

Extract of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023

(Rs. In lakhs)

Table with 7 columns: Sl. No., Particulars, Standalone Quarter ended, Quarter ended, Nine months ended, Consolidated Quarter ended, Quarter ended, and Nine months ended.

Notes: 1 The above is an extract of the detailed format of Standalone and Consolidated Financial Results vide Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2 The above Standalone and Consolidated Financial Results have been reviewed by the Audit Committee in its meeting held on February 8, 2024 and approved by the Board of Directors in their meeting held on February 9, 2024.

3 (i) In standalone financial statements, during the quarter ended December 31, 2023, the Exchange has received excess contribution of Rs.15 lakh and Rs. 590 lakh during the half year ended September 30, 2023 from Core SGF (post tax liability of Core SGF) from its subsidiary company, National Commodity Clearing Ltd.(NCCL) aggregating to Rs. 605 lakh for the nine months period ended December 31, 2023, due to revision in computation of Core Settlement Guarantee Fund (SGF) in Commodity Derivatives Segment and the same is credited to the statement of profit and loss and shown as an Exceptional item.

For and on behalf of the Board of Directors Sd/- Arun Raste Managing Director & Chief Executive Officer DIN - 08561128

Place: Mumbai Date: February 9, 2024



Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

Registered Office: No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India.
Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(Amount in INR crores except per share data)

Table with columns for Particulars, Consolidated (Quarter ended, Nine Months ended, Year ended), and Standalone (Quarter ended, Nine Months ended, Year ended). Rows include Total Income, Net Profit, Total Comprehensive Income, Equity Share Capital, Earnings per share, etc.

• The unaudited consolidated and standalone financial results of the Company for the quarter and nine months ended December 31, 2023 have been reviewed by the Audit Committee on February 08, 2024 and approved by the Board of Directors at its meeting held on February 08, 2024.
• The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial statements is made available on the Company's website at www.asterdmhealthcare.com/investors and stock exchange website at BSE https://www.bseindia.com/ and NSE https://www.nseindia.com/.
• The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.

For Aster DM Healthcare Limited
Sd/-
Alisha Moopen
Deputy Managing Director
DIN: 02432525

Place: Dubai
Date: February 08, 2024

CONCORD BIOTECH LIMITED

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat
Phone No. : +91-79-68138700 || Fax : +91-79-68138725 || CIN : L24230GJ1984PLC007440
Email Id : complianceofficer@concordbiotech.com || Website : www.concordbiotech.com
Regd. Office & Plant : 1482-86, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India
Phone No. : +91-2714-222604, 398200 || Fax : +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

(Rs. In lakhs except per share data)

Table with columns for Particulars, Standalone (Unaudited), and Consolidated (Unaudited). Rows include Total Income from Operations, Net Profit, Total Comprehensive Income, Equity Share Capital, Reserves, Earnings Per Share, etc.

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly / Nine Months Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly / Nine Months Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com
(b) #- Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules /AS Rules, whichever is applicable.
(c) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February 08, 2024.
For and on behalf of board of directors of Concord Biotech Limited

Place : Ahmedabad
Date : February 8, 2024
Ankur Vaid
Joint Managing Director & CEO - DIN : 01857225

Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481
Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com
CIN : L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023

Rupees in Million

Table with columns for Sr. No., Particulars, 3 Months ended, Preceding 3 Months ended, Corresponding 3 Months ended, Year to date figures for the current period ended, Year to date figures for the previous period ended, Previous year ended. Rows include Total income from operations, Net Profit, Profit/Loss, Total Comprehensive Income, etc.

Note: [1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

By Order of the Board,
For Zydus Lifesciences Limited,
Dr. Sharvil P. Patel
Managing Director
DIN: 00131995

Date: February 9, 2024
Place: Ahmedabad

PSP Projects Limited

CIN :L45201GJ2008PLC054868
Registered Office : PSP House, Opp. Celesta Courtyard, Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058
Website : www.pspprojects.com

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023

Table with columns for Sr. No., Particular, Consolidated (Quarter Ended, Nine Months Ended). Rows include Total Income from Operations, Net Profit, Net Profit for the period, Total Comprehensive Income, etc.

Notes:
1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 09, 2024.
2. Additional information on Unaudited Standalone Financial Results are as follows:

Table with columns for Particular, Standalone (Quarter Ended, Nine Months Ended). Rows include Revenue from Operations, Profit/Loss before tax and Exceptional item, Profit/Loss after tax and Exceptional item.

3. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited (URL: www.bseindia.com), National Stock Exchange of India Limited (URL: www.nseindia.com) and on company's website (URL: www.pspprojects.com)
For and on behalf of Board of Directors of PSP Projects Limited
Sd/-
Prahaldhrai S. Patel
Chairman, Managing Director & CEO
DIN: 00037633

Place : Ahmedabad
Date : February 9, 2024

BERAR FINANCE LIMITED

CIN:U65929MH1990PLC057829
Regd. Office: AVINISHA TOWER,MEHADIA CHOWK, DHANTOLI, NAGPUR - 440 012. Ph no.0712-6663999
Website: www.berarfinance.com
E-mail: investor.relations@berarfinance.com

Extract of Financial Results for the quarter ended December 31, 2023

[Regulation 52(8) read with Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)]

Table with columns for Sr. No., PARTICULARS, Quarter ended Dec. 31, 2023, Quarter ended Dec. 31, 2022, Year ended March 31, 2023. Rows include Total Income from Operations, Net Profit, Total Comprehensive Income, etc.

Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind AS Rules.
* Not annualised for quarter ended December 31, 2023 and December 31, 2022.

Notes :
a) The above Results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on February 09, 2024.
b) The above is an extract of the detailed format of financial results filed with the BSE Limited ("Stock Exchange") under Regulation 52 of the SEBI Listing Regulations. The full format of the financial results is available on the website of the Stock Exchange i.e. www.bseindia.com and on the website of the Company i.e. www.berarfinance.com
c) For the other line items referred in regulation 52 (4) of the SEBI Listing Regulations, pertinent disclosures have been made to BSE Limited and can be accessed on www.bseindia.com. and on the website of the Company i.e. www.berarfinance.com
d) This Extract of Financial Results has been prepared in accordance with the requirement of Regulation 52 of the SEBI Listing Regulations read with Operational Circular bearing reference no. SEBI/HO/DDHS/DDHS_Div1/P/CIR/2022/000000103 dated July 29, 2022 as amended ("Circular").

For and on behalf of Board of Directors of Berar Finance Limited
Sd/-
(Sandeep Jawanjali)
Managing Director
DIN: 01490654
Place: Nagpur
Date: February 09, 2024



National Commodity & Derivatives Exchange Limited

CIN : U51909MH2003PLC140116
Regd Office : Akrti Corporate Park, 1st Floor, L.B.S. Road, Near G.E.Garden, Kanjurmarg West, Mumbai, Maharashtra 400078

Ph: 022-66406789 | Email: askus@ncdex.com | Website: www.ncdex.com

Extract of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023

(Rs. In lakhs)

Table with columns for Sl. No., Particulars, Standalone (Quarter ended, Quarter ended, Nine months ended), Consolidated (Quarter ended, Quarter ended, Nine months ended). Rows include Total Income from operations, Net Profit, Total Comprehensive Income, Equity Share Capital, Reserves, Earnings Per Share, etc.

Notes:
1 The above is an extract of the detailed format of Standalone and Consolidated Financial Results vide Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financials are available on our website www.ncdex.com
2 The above Standalone and Consolidated Financial Results have been reviewed by the Audit Committee in its meeting held on February 8, 2024 and approved by the Board of Directors in their meeting held on February 9, 2024.

3 (i) In standalone financial statements, during the quarter ended December 31, 2023, the Exchange has received excess contribution of Rs.15 lakh and Rs. 590 lakh during the half year ended September 30,2023 from Core SGF (post tax liability of Core SGF) from its subsidiary company, National Commodity Clearing Ltd.(NCCL) aggregating to Rs. 605 lakh for the nine months period ended December 31,2023, due to revision in computation of Core Settlement Guarantee Fund (SGF) in Commodity Derivatives Segment and the same is credited to the statement of profit and loss and shown as an Exceptional item.
(ii) In standalone financial statements, during the quarter ended December 31, 2023, the Exchange has sold 8.71% (31 lakh equity share) of its stake in its subsidiary, NCDEX e-Markets Limited (NeML), to its wholly owned subsidiary, NCCL, for a consideration of Rs. 3,000.80 lakh. The profit earned on the said stake sale of Rs. 2,691 lakh has been credited to the statement of profit and loss and shown as an exceptional item.
(iii) In case of subsidiary NCDEX e Markets Limited (NeML), NeML has incurred expenses of Rs. 36 Lakhs on newly incorporated Joint Venture during the nine months ended December 31, 2022. As the approval for commencement of business is awaited from the relevant authority, the said expenses have been shown as an exceptional item.
(iv) In case of subsidiary NCDEX e Markets Limited (NeML), during the nine months ended December 31, 2023, exceptional Income of Rs 44 lakh is on account of income booked for recovery of Preincorporation and other expenses incurred on behalf of newly incorporated JV, prior to receipt of approval from Regulatory authorities.

For and on behalf of the Board of Directors
s/-
Arun Raste
Managing Director & Chief Executive Officer
DIN - 08561128

Place: Mumbai
Date: February 9, 2024

